Drug Profile
Myristyl nicotinate
Alternative Names: Nia-114; Niacin prodrug - Niadyne Pharma; Tetradecyl nicotinateLatest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator Niadyne
- Developer Niadyne; University of Arizona
- Class Antineoplastics; Nicotinic acids; Skin disorder therapies
- Mechanism of Action GPR109A receptor agonists; GPR109B receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Plaque psoriasis; Skin cancer
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Plaque-psoriasis in USA (Topical, Cream)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Skin-cancer(Prevention) in USA (Topical, Cream)